Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January 5, 2023, the Board of Directors (the "Board") of ZyVersa
Therapeutics, Inc., a Delaware corporation (the "Company" or "ZyVersa"),
appointed James Sapirstein, Gregory Freitag, and Katrin Rupalla to serve as
members of the board to fill the three vacancies created as a result of the
business combination between ZyVersa Therapeutics, Inc., a Florida corporation
("Old ZyVersa") with Larkspur Health Acquisition Corp. ("Larkspur"), which was
consummated on December 12, 2022 (the "Business Combination"). As previously
disclosed, pursuant to the agreement governing the terms of the Business
Combination (the "Business Combination Agreement"), the Board was to be
increased to seven members with Old ZyVersa and/or Stephen Glover appointing six
members of the Board and Larkspur appointing one member of the Board. Upon
consummation of the Business Combination, the Board consisted of four members,
three appointed by Old ZyVersa and one appointed by Larkspur. As such, the three
directors described herein are being appointed pursuant to the provisions set
forth in the Business Combination Agreement.
Mr. Sapirstein, Mr. Freitag, and Dr. Rupalla will hold these positions until the
next annual meeting of the Company's stockholders or until his/her successor is
elected and qualified, subject to his/her earlier resignation or removal.
Mr. Sapirstein is currently the Chairman, Chief Executive Officer and President
of First Wave BioPharma (NASDAQ: FWBI). Mr. Sapirstein started his career in
smaller biotech companies when he later joined Gilead Sciences, Inc. in order to
lead the Global Marketing team in its launch of Viread (tenofovir). In 2002, he
accepted the position of Executive Vice President, Metabolic and Endocrinology,
for Serono Laboratories. Later, in 2006, he became the founding Chief Executive
Officer of Tobira Therapeutics, then a private company. Tobira Therapeutics was
acquired by Allergan in 2016. In 2012, Mr. Sapirstein became the Chief Executive
Officer of Alliqua, Inc. Thereafter, he served as Chief Executive Officer of
Contravir Pharmaceuticals from March 2014 until October 2018. All of these are
publicly listed companies. Mr. Sapirstein has raised over $300 Million dollars
in venture capital and public capital markets financing in his various
engagements as Chief Executive Officer. He was named as a Finalist for the Ernst
& Young Entrepreneur of the Year award in 2015 as well as in 2016. The Company
believes Mr. Sapirstein is qualified to serve as a member of the Board because
of his extensive experience as an executive in the biotech and pharmaceutical
sectors and as a director for multiple public companies in such sectors.
In addition to being a board member of First Wave Bio Pharma, Mr. Sapirstein
currently holds board positions on Enochian Biosciences (NASDAQ: ENOB) and Blue
Water Vaccines (NASDAQ: BWV). He was Chairman of the Board for BioNJ, an
association of biopharma industries in New Jersey from February 2017 to February
2019. In addition, he is a member of the Board of Directors for BIO
(Biotechnology Innovation Organization), the leading biotechnology trade
organization promoting public policy and networking in the healthcare space,
where he sits on the Emerging Companies Section Governing Board.
Mr. Sapirstein will serve as a member of the Company's Compensation Committee
and the Nominating and Corporate Governance Committee.
Mr. Sapirstein will receive an annual cash retainer fee of $40,000 (pro-rated
for the current year) and an additional cash retainer of $7,500 and $4,000,
respectively, for his service as a member of the Compensation Committee and the
Nominating and Corporate Governance Committee. Mr. Sapirstein will also receive
an initial and annual option grant pursuant to the Company's previously
disclosed 2022 Omnibus Equity Incentive Plan (the "2022 Plan"). Reference is
made to the disclosure in the final Proxy Statement/Prospectus filed with the
U.S. Securities and Exchange Commission on November 14, 2022 (the "Proxy
Statement") beginning on page 254 in the section entitled "Management of the
Combined Entity Following the Business Combination - Compensation of Directors
and Executive Officers - Director Compensation."
There are no transactions between Mr. Sapirstein and the Company that would be
reportable under Item 404(a) of Regulation S-K.
Mr. Freitag is currently a member of the board of directors of PDS Biotechnology
Corporation (NASDAQ: PDSB), a clinical-stage immunotherapy company developing a
growing pipeline of targeted cancer and infectious disease immunotherapies based
on its proprietary Veramune and Infectimune T cell-activating platforms and
Axogen, Inc. Mr. Freitag was Axogen's Special Counsel from June 2020 until March
2021, General Counsel from September 2011 until June 2020, Chief Financial
Officer from September 2011 until May 2014 and August 2015 until March 2016, and
Senior Vice President Business Development from May 2014 until October 2018. Mr.
Freitag was the Chief Executive Officer, Chief Financial Officer, and a member
of the board of directors of LecTec Corporation, an intellectual property
licensing and holding company that merged with Axogen Inc. in September 2011,
from June 2010 until September 2011. From May 2009 to the present, Mr. Freitag
has been a principal of FreiMc, LLC, a healthcare and life science consulting
and advisory firm he founded that provides strategic guidance and business
development advisory services. Prior to founding FreiMc, LLC, Mr. Freitag was a
Director of Business Development at Pfizer Health Solutions, a former subsidiary
of Pfizer, Inc., from January 2006 until May 2009. From July 2005 to January
2006, Mr. Freitag worked for Guidant Corporation in the business development
group. Prior to Guidant Corporation, Mr. Freitag was the Chief Executive Officer
of HTS Biosystems, a biotechnology tools start-up company, from March 2000 until
its sale in early 2005. Mr. Freitag was the Chief Operating Officer, Chief
Financial Officer and General Counsel of Quantech, Ltd., a public point of care
diagnostic company, from December 1995 to March 2000. Prior to that time, Mr.
Freitag practiced corporate law in Minneapolis, Minnesota.
Mr. Freitag holds a J.D. from the University of Chicago and a B.A. in Economics
& Business and Law & Society from Macalester College, Minnesota. The Company
believes Mr. Freitag's qualifications to serve on the Board and as the chair of
the Company's Audit Committee include his proven leadership and experience as a
senior-level executive, his particular knowledge of public companies, including
reporting, compliance and financial markets related thereto, his finance
management and legal expertise and over 30 years of experience in the life
sciences sector.
Mr. Freitag will serve as the chair of the Company's Audit Committee and as a
member of the Company's Nominating and Corporate Governance Committee.
Mr. Freitag will receive an annual cash retainer fee of $40,000 (pro-rated for
the current year) and an additional cash retainer of $18,500 for his service as
chair of the Audit Committee and $4,000 as a member of the Corporate Governance
Committee. Mr. Freitag will also receive an initial and annual option grant
pursuant to the Plan. Reference is made to the disclosure in the Proxy Statement
beginning on page 254 in the section entitled "Management of the Combined Entity
Following the Business Combination - Compensation of Directors and Executive
Officers - Director Compensation."
There are no transactions between Mr. Freitag and the Company that would be
reportable under Item 404(a) of Regulation S-K.
Dr. Rupalla is a co-founder and Chief Executive Officer of Ymmunobio AG, an
immuno-oncology biotech launched in December 2021. She is currently the Chair of
the Board of Directors of Ambrx Biopharma Inc. (NYSE: AMAM) and a member of the
Board of Directors of the Cancer Drug Development Fund.
Dr. Rupalla previously served as a member of the Board of Directors of 4D Pharma
PLC (UK AIM & NASDAQ: DDDD.L) from September 2020 until July 2022. Dr. Rupalla
has previously served in senior positions at Roche, Celgene, Bristol-Myers
Squibb ("BMS") and Lundbeck. While at BMS from 2012 to 2019, Dr. Rupalla was
Vice President Head Research & Development, China and Global Development Team
Leader for Opdivo®/Yervoy® in China, and then Vice President, Head Oncology
Global Regulatory Sciences. Throughout her 25-year career, she has led regional
and global teams responsible for obtaining approvals for multiple new
therapeutics and indications, including Opdivo®, Yervoy®, Rituxan®, Xeloda®,
Avastin ®, Revlimid® and Vidaza®, among others. Between 2019 and 2021, Dr.
Rupalla previously served as Senior Vice President, Global Head Regulatory
Affairs, Medical Documentation and Research & Development Quality at Lundbeck, a
leading biopharmaceutical developing novel therapeutics for diseases of the
central nervous system. The Company believes Dr. Rupalla is qualified to serve
on the Board because of her senior and executive leadership experience in
biotech and pharmaceutical companies, her extensive knowledge of the regulatory
and compliance issues facing companies in these sectors and her experience as a
director of public companies.
Dr. Rupalla has a Ph.D in CNS Pharmacology from the Philipps-University Marburg,
Germany, and an MBA from Jones International University, Colorado, U.S.
Dr. Rupalla will serve as the chair of the Nominating and Corporate Governance
Committee.
Dr. Rupalla will receive an annual cash retainer fee of $40,000 (pro-rated for
the current year) and an additional cash retainer of $8,000 for her service as
chair of the Nominating and Corporate Governance Committee of the Board. Dr.
Rupalla will also receive an initial and annual option grant pursuant to the
Plan. Reference is made to the disclosure in the Proxy Statement beginning on
page 254 in the section entitled "Management of the Combined Entity Following
the Business Combination - Compensation of Directors and Executive Officers -
Director Compensation."
There are no transactions between Dr. Rupalla and the Company that would be
reportable under Item 404(a) of Regulation S-K.
© Edgar Online, source Glimpses